Roth Capital Partners analyst Adam Walsh says a third controlled celiac disease dataset supporting IL-15 blockade increases the potential value of Equillium’s (Equillium Stock Quote, Chart, News, Analysts, Financials NASDAQ:EQ) EQ302 program. In an Oct. 8 update, Walsh reiterated his “Buy” rating and US$12.00 target on Equillium. Walsh said Belgian-Dutch pharmaceutical company argenx reported positive […]
Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong readout from its EoE program. In a recent update, Uddin maintained his “Speculative Buy” rating and $14.00 target on Eupraxia. Victoria-based Eupraxia is a drug delivery company developing EP-104GI for eosinophilic esophagitis, or EoE. The […]
Share
Tweet
Share
